Department of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.
Radiother Oncol. 2012 Mar;102(3):412-5. doi: 10.1016/j.radonc.2011.07.026. Epub 2011 Sep 2.
Tolerability to gemcitabine radiochemotherapy was evaluated in 33 patients with inoperable, locally advanced transitional-cell bladder cancers. The dose of 75 mg/m(2) gemcitabine once a week, concurrently with standard radiotherapy of 60 Gy/6 weeks, was found to be acceptable. Eighty-one percentage of 3-year local progression-free survival suggests efficiency warranting further studies.
33 例不能手术的局部晚期移行细胞膀胱癌患者接受吉西他滨放化疗的耐受性评估。每周一次、剂量为 75mg/m(2)的吉西他滨与标准的 60Gy/6 周放疗同时应用，被认为是可接受的。3 年局部无进展生存率为 81%，表明其疗效值得进一步研究。
